Source comparison

Bodybuilding Peptides 2026 Update: Legacy vs Current Compounds

GH Secretagogue Ipamorelin (solo) CJC-1295 + ipamorelin combination CJC extends GH pulse duration; ipamorelin maintains amplitude. Synergistic effect produces 3–4× IGF-1 elevation vs ipamorelin alone 100mcg ipamorelin + 2mg CJC-1295 nightly Still viable for re

This comparison does not assign a generated winner or score.

GH Secretagogue
Ipamorelin (solo)
CJC-1295 + ipamorelin combination
CJC extends GH pulse duration; ipamorelin maintains amplitude. Synergistic effect produces 3–4× IGF-1 elevation vs ipamorelin alone
100mcg ipamorelin + 2mg CJC-1295 nightly
Still viable for researchers prioritising GH/IGF-1 axis; dual agonists have replaced it for recomposition goals
Recomposition Agent
None (GH secretagogues used off-label)
Survodutide, mazdutide
GLP-1/GIP dual activation targets nutrient partitioning directly. No systemic GH elevation required
3–6mg weekly (subcutaneous)
The single biggest protocol shift in 2026; replaces GH + T3 stacks for fat loss with lean mass preservation
Tissue-Selective Anabolic
Oral SARMs (ostarine, RAD-140)
SLU PP 332
Peptide-based delivery bypasses hepatic metabolism; higher tissue selectivity ratio (>10:1 vs 3:1 for oral SARMs)
2–5mg daily (subcutaneous)
Early-stage research compound; not a direct replacement yet but represents the next generation of selective androgens
Myostatin Inhibitor
None (gene therapy only)
Follistatin-344, ACE-031
First pharmacologically viable myostatin blockers with stable synthesis and defined half-lives
100–200mcg every 48 hours
Niche application; useful for breaking through genetic plateaus but not a first-line compound
Recovery/Healing
BPC-157, TB-500
Still BPC-157, TB-500 (no replacement)
No mechanistic improvement. These remain the gold standard for angiogenesis and tissue repair
BPC-157: 250–500mcg daily; TB-500: 2–5mg twice weekly
2026 update: no changes; these compounds weren't replaced because they address a different pathway (wound healing, not anabolism)